Related Experiment Videos
Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine
Nikolai G Rainov1, Ariane Söling
1The University of Liverpool, Division of Neuroscience, The Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK. N.G.Rainov@liverpool.ac.uk
Current Opinion in Molecular Therapeutics
|October 27, 2005
Summary
TransMID, a novel transferrin-mediated diphtheria toxin delivery system, is in phase III trials for treating recurrent high-grade glioma and other brain cancers.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- High-grade glioma presents a significant challenge in adult neuro-oncology.
- Recurrent and inoperable brain tumors have limited treatment options.
- Targeted drug delivery systems are crucial for improving therapeutic efficacy and reducing systemic toxicity.
Purpose of the Study:
- To evaluate the efficacy and safety of TransMID, a transferrin-mediated diphtheria toxin delivery system.
- To investigate TransMID for the treatment of adult, recurrent, inoperable, high-grade glioma.
- To explore TransMID's potential in various brain cancer indications, including early, metastatic, and pediatric brain cancers.
Main Methods:
- Development of TransMID, a targeted drug delivery system utilizing transferrin-mediated diphtheria toxin.
- Clinical investigation across multiple brain cancer subtypes.
- Ongoing phase III clinical trials to assess therapeutic outcomes.
Main Results:
- TransMID is under active investigation in phase III clinical trials.
- The system targets brain tumors by leveraging the transferrin receptor pathway.
- Potential application demonstrated across adult and pediatric brain cancer types.
Conclusions:
- TransMID represents a promising targeted therapy for high-grade glioma.
- Further clinical evaluation is ongoing to establish its role in brain cancer treatment.
- The transferrin-mediated delivery system holds potential for various oncological applications.